Gut microbiome and cancer immunotherapy.

07:00 EST 23rd January 2019 | BioPortfolio

Summary of "Gut microbiome and cancer immunotherapy."

Microbiome is becoming crucial in that the balance between human health and disease can be mediated by the gut microbiome. The gut microbiome can modulate the host immune system both locally and systemically. Cancer immunotherapy has emerged as a promising way in the treatment of patients with cancer. Accumulating evidence supports that microbiome affects the therapeutic efficacy of cancer immunotherapy, particularly immune checkpoint inhibitors. Here, we discuss the mutual relationship among gut microbiome, cancer, immunity, and cancer immunotherapy, with a focus on immunotherapy. Also, we briefly introduce the relevant challenges that affect the therapeutic efficacy and present the possible solutions.


Journal Details

This article was published in the following journal.

Name: Cancer letters
ISSN: 1872-7980


DeepDyve research library

PubMed Articles [14803 Associated PubMed Articles listed on BioPortfolio]

The role of the microbiome in immunologic development and its implication for pancreatic cancer immunotherapy.

Our understanding of the microbiome and its role in immunity, cancer initiation, and cancer progression has evolved significantly over the past century. The "germ theory of cancer" was first proposed ...

The microbiome and cancer for clinicians.

The human microbiome is an emerging target in cancer development and therapeutics. It may be directly oncogenic, through promotion of mucosal inflammation or systemic dysregulation, or may alter anti-...

The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.

Gut microbiome affecting the responses to immune checkpoint inhibitors (ICIs) against advanced non-small cell lung cancer (NSCLC) has been investigated in western population. However, considering pree...

The next age of immunotherapy: optimisation, stratification and therapeutic synergies.

Cancer immunotherapy has entered a phase of broad application in the treatment of patients with haematologic and solid tumours. From first steps to standard of care, immunotherapy has established its ...

Cancer-testis antigens: An update on their roles in cancer immunotherapy.

Several recent studies have assessed suitability of tumor antigens for immunotherapy. Based on the restricted expression pattern in somatic tissues, cancer-testis antigens (CTAs) are possible candidat...

Clinical Trials [10555 Associated Clinical Trials listed on BioPortfolio]

Time Longitudinal Study of the Microbiome in Colorectal Cancer Subjects

Researchers are trying to determine whether certain microbiome cause cancer or whether they are part of the microbiome in the gut due to the presence of cancer.

The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer

The human oral cavity is a diverse habitat that contains approximately 700 prokaryotic species. The oral microbiome is comprised of 44% named species, 12% isolates representing unnamed spe...

Microbiome in Lung Cancer and Other Malignancies

This research study will characterize the nasal, oral and fecal microbiome in patients with lung cancer and other malignancies, and correlate the data with treatment response and toxicitie...

Effects of H.Pylori Eradication on Microbiome

The aim of this Project is, within the scope of industrial research, to evaluate the long term effects of H.pylori eradication on microbiome (gut microbiome, upper respiratory tract microb...

Nutritional Intake and Gut Microbiome

Pediatric obesity has been increasing in prevalence, but concerns have been raised around the world because no treatment has been found. Recently, however, research on gut microbiome has b...

Medical and Biotech [MESH] Definitions

Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)

Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumor antigen and other markers (often by RADIOIMMUNOASSAY), studies of cellular or humoral immunity in cancer etiology, IMMUNOTHERAPY trials, etc.

Monocytes made cytotoxic by IN VITRO incubation with CYTOKINES, especially INTERFERON-GAMMA. The cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.

Quick Search


DeepDyve research library

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Searches Linking to this Article